NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
On November 16, 2016, Nexus Biopharma, Inc. (the Company) filed
with the United States Securities and Exchange Commission
itsConsent SolicitationStatement onSchedule 14A(the Consent
SolicitationStatement) seeking stockholder approval for the
matter set forth therein. As of December 20, 2016, the expiration
date, the Company had received writtenconsentsapproving the
matter set forth in theConsent Solicitation Statement. As of the
record date for theConsent Solicitation Statement, there were
64,300,000 shares of common stock issued and outstanding.
The proposal set forth in theConsent SolicitationStatement was
approved and theresultsof the voting are set forth below:
|
Votes For |
|
|
Votes Against |
|
|
Abstentions |
||
|
Proposal 1: Approval of an amendment to the |
34,222,163 |
63,201 |
1,000 |
|||||
About NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS)
Nexus Biopharma, Inc., formerly Plata Resources, Inc., is engaged in developing a weight loss drug that activates the 5′ adenosine monophosphate-activated protein kinase (AMPK) metabolic pathway. The Company is developing a treatment for obesity. It has worked for the virtual screening, assay development and optimization, compound selection and screening, and active-to-hit work to support hit identification of inhibitors of Fyn kinase. It is also focused on developing a drug for the blood chemistry improvements for type 2 diabetes. The Company has completed pre-clinical trials of the pharmaceutical activation of AMPK metabolic pathway. The Company focuses on advancing these to pre-Investigational New Drug (IND) trials in preparation for the United States Food and Drug Administration (FDA) human trials of a drug. NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS) Recent Trading Information
NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS) closed its last trading session up +0.001 at 0.340 with 61,974 shares trading hands.